RBOT — Vicarious Surgical Inc.

Summary of Vicarious Surgical Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Operating Expenses: $11.5 million, down 35% from $17.8 million in Q3 2024.
• Research and Development Expenses: $8 million, decreased from $10.8 million year-over-year.
• General and Administrative Expenses: $3.2 million, down from $5.7 million in Q3 2024.
• Sales and Marketing Expenses: $350,000, a significant reduction from $1.2 million in the same quarter last year.
• GAAP Net Loss: $11.1 million or $1.86 per share, improved from a loss of $17.1 million or $2.90 per share in Q3 2024.
• Non-GAAP Adjusted Net Loss: $11.3 million or $1.91 per share, compared to $17 million or $2.87 per share in Q3 2024.
• Cash Position: Ended Q3 with approximately $13.4 million in cash and equivalents, with a cash burn rate of $10.5 million for the quarter.
• Full Year Cash Burn Expectation: Anticipated to be around $50 million for 2025.

2. Strategic Updates and Business Highlights

• Leadership Transition: Stephen From has been in the CEO role for over three months, focusing on execution and operational efficiency.
• Design Freeze Target: Aiming for design freeze of the production-equivalent surgical system by year-end 2026, which is critical for clinical trials and commercialization.
• Cost Reduction Initiatives: Implemented measures to reduce cash burn, including restructuring teams and reducing headcount by about 15%.
• Outsourcing Strategy: Engaged a consulting firm to evaluate outsourcing opportunities to enhance capital efficiency while maintaining core technological development.
• Communication Enhancements: Plans to increase transparency through regular updates on development progress via LinkedIn and the Investor Relations website.

3. Forward Guidance and Outlook

• Cash Burn Reduction: Management is confident in achieving a material reduction in cash burn for 2026.
• Outsourcing Impact: While some disruption is expected during the outsourcing process, the timeline for design freeze remains a priority.
• Future Communication: Regular updates will be provided to keep stakeholders informed about progress and challenges.

4. Bad News, Challenges, or Points of Concern

• Cash Burn Rate: The current cash burn rate is significant, and while reductions are planned, the company still faces financial pressure.
• Outsourcing Risks: Potential disruptions during the outsourcing process could affect timelines, although management is working to mitigate these risks.
• Recent Layoffs: A reduction in workforce may raise concerns about the company’s operational capacity and morale.

5. Notable Q&A Insights

• Timeline Confirmation: The timeline for achieving design freeze remains targeted for mid-2026, despite the outsourcing initiative.
• Development Testing: Surgeons are actively testing intermediate builds in the company’s own operating room, showing promising results in surgical efficiency, particularly in suturing times.
• Consulting Engagement: The consulting firm PA Consulting is expected to complete its analysis by the end of November, which will inform the outsourcing strategy.
• Strong Relationships with Healthcare Partners: Ongoing engagement with hospital systems and surgeons is positive, with feedback being actively incorporated into product development.

This summary encapsulates the key points from Vicarious Surgical's Q3 2025 earnings call, highlighting financial performance, strategic initiatives, and future outlook while addressing challenges and insights from the Q&A session.